Analyzing Aurinia Pharmaceuticals (NASDAQ:AUPH) & Bicycle Therapeutics (NASDAQ:BCYC)

Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Free Report) and Bicycle Therapeutics (NASDAQ:BCYC – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Valuation & Earnings

This table compares Aurinia Pharmaceuticals and Bicycle Therapeutics”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aurinia Pharmaceuticals $283.05 million 7.87 $287.20 million $2.29 7.26
Bicycle Therapeutics $72.86 million 3.62 -$218.96 million ($2.03) -1.86

Aurinia Pharmaceuticals has higher revenue and earnings than Bicycle Therapeutics. Bicycle Therapeutics is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. Comparatively, 86.2% of Bicycle Therapeutics shares are held by institutional investors. 10.4% of Aurinia Pharmaceuticals shares are held by company insiders. Comparatively, 22.0% of Bicycle Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and price targets for Aurinia Pharmaceuticals and Bicycle Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aurinia Pharmaceuticals 0 3 2 1 2.67
Bicycle Therapeutics 2 3 5 0 2.30

Aurinia Pharmaceuticals currently has a consensus target price of $17.33, suggesting a potential upside of 4.29%. Bicycle Therapeutics has a consensus target price of $13.57, suggesting a potential upside of 259.98%. Given Bicycle Therapeutics’ higher probable upside, analysts clearly believe Bicycle Therapeutics is more favorable than Aurinia Pharmaceuticals.

Profitability

This table compares Aurinia Pharmaceuticals and Bicycle Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Aurinia Pharmaceuticals 97.68% 22.99% 17.99%
Bicycle Therapeutics -169.75% -26.02% -22.30%

Volatility and Risk

Aurinia Pharmaceuticals has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500. Comparatively, Bicycle Therapeutics has a beta of 1.59, indicating that its stock price is 59% more volatile than the S&P 500.

Summary

Aurinia Pharmaceuticals beats Bicycle Therapeutics on 10 of the 15 factors compared between the two stocks.

About Aurinia Pharmaceuticals

(Get Free Report)

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

About Bicycle Therapeutics

(Get Free Report)

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.